SOURCE: Wound Management Technologies, Inc.

Wound Management Technologies, Inc.

October 21, 2014 08:30 ET

Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors

ADDISON, TX--(Marketwired - Oct 21, 2014) - Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.

Ronald Goode, Ph.D., has an extensive background in healthcare and brings a wealth of knowledge from a management and clinical perspective. Dr. Goode has served as President and CEO of Unimed Pharmaceuticals and eXegenics and held key management positions at Pfizer Pharmaceuticals and G.D. Searle & Co. He is currently the President and CEO of the Goode Group, a consulting firm advising Boards of Directors, senior executives and investment funds. Dr. Goode has also supervised clinical development programs for such blockbuster drugs as Pfizer's Procardia XL, Searle's Ambien and Unimed's Androgel. His experience extends globally where he presently serves on the Board of Directors of Hikma Pharmaceuticals. Under Sarbanes-Oxley, Dr. Goode is qualified to serve as an Audit Committee Financial Expert. He received his Ph.D. in Microbiology from the University of Georgia.

"The opportunities that Wound Management Technologies have developing in the pipeline were extremely appealing when I took a seat on the board. With my background in healthcare, I look forward to guiding the company as it advances on its strategic growth initiatives. I am excited about the prospects of a company with a highly effective management team coupled with such an effective product as CellerateRX®," comments Dr. Goode. 

Jeffrey Lewis currently serves as President of the Institute for Healthcare Innovation. Mr. Lewis spent many years working in Congress and is the former President of the Heinz Family Philanthropies. He was an instrumental player in building healthcare solutions for both public and private employers.

Having worked to manage the dramatic swell in healthcare costs, Mr. Lewis comments, "I am excited to join the board of a company like Wound Management Technologies that offers an economical solution to wound care that doesn't sacrifice the efficacy of the product. If we are to ever control the healthcare cost tsunami, we need practical solutions like CellerateRX®. The product represents a new market-based solution to manage wound care."

About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX®, which is FDA-cleared for all wound types except 3rd degree burns. The wound care products are reimbursable under Medicare Part B and the surgical products are reimbursed as part of a procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit

To download Wound Management Technologies' investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit to download on your iPhone and iPad or for your Android mobile device.

Information about Forward-Looking Statements
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Contact Information